Newborn Screening Market Size
The global newborn screening market size was estimated at USD 973.58 million in 2025 and is projected to reach USD 1,815.42 million by 2033, growing at a CAGR of 8.1% from 2026 to 2033.
Newborn screening tests newborns for certain disorders such as phenylketonuria (PKU), Cystic Fibrosis, sickle cell disease, critical congenital heart disease, hearing loss, and others. This testing is typically performed before the baby leaves the hospital. Early detection and treatment can help prevent newborns' intellectual and physical disabilities and life-threatening illnesses.
Newborn Screening Market Summary
| Metrics | Details |
| Market CAGR | 8.1% |
| Segments Covered | By Product, By Test Type, By Application, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get Free Sample Click Here
Market Dynamics
The newborn screening market's growth is driven by several factors, such as a rising neonatal population base and an increase in cases of congenital diseases in newborns. In addition, increasing healthcare awareness, benefits offered by newborn screening programs, technological advancements in screening, and increasing government funding and support are also driving the growth of the newborn screening market globally.
Technological advancements in newborn screening are expected to drive market growth.
According to the American Association for Clinical Chemistry, the advancement of tandem mass spectrometry (MS/MS) has aided the rapid spread of neonatal screening. Before the introduction of MS/MS, an aliquot of the specimen was required to test for each disease. MS/MS is a multi-analyte technique that detects many disorders from a single blood specimen more rapidly, precisely, and affordably than earlier methods. Physicians may now diagnose more metabolic problems before symptoms appear, saving neonates from death or irreversible health concerns. The application of MS/MS technology has been critical in expanding neonatal screening. Further technological advancements, such as sequencing, should allow laboratories to screen for more disorders.
In addition, the World Health Organization implemented a program to safeguard the health of children globally, in which numerous policies and initiatives have been taken by the U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), Japan's Society of Obstetrics and Gynecology (JSOG), the U.K. (PEACH), and advocacy groups. Thus, from the above statements, the market is expected to drive in the forecast period.
Restraint:
However, the lack of improved healthcare infrastructure, trained professionals, and socioeconomic barriers are some of the major factors restraining the growth of the global newborn screening market.
Industry Analysis
The global market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.
Market Segmentation
Blood Spot Test segment is expected to hold the largest market share in the market.
The blood spot test dominated the global market for newborn screening. Blood collection from a newborn’s heel within 24–48 hours of birth on the screening card for diagnosis of over 50 conditions is termed heel stick or dried blood spot test (DBS). These screening cards are labeled using unique codes and contain no additional identity information. Autism, lymphomas, leukemia and many other metabolic conditions can be diagnosed through this test. The card used for testing is provided free in North America as a plan to promote higher procedure volume. Therefore, it has increased the demand for blood spot tests. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.
Market Geographical Shares
North American region is expected to hold the largest market share in the global newborn screening market.
North America dominates the global market for newborn screening. The rising prevalence of congenital disorders. For instance, according to the Centers for Disease Control and Prevention, a newborn with a congenital impairment is born every 4 1/2 minutes in the United States. Every year, one in every 33 newborns born in the United States has a congenital disability. This equates to approximately 120,000 babies.
Furthermore, congenital impairments account for 1 in every 5 deaths in the first year of life. Congenital impairments are serious conditions that can have long-term consequences. Total hospital costs for children and adults with birth abnormalities in the United States surpassed $2.6 billion per year, not considering outpatient care or various provider charges. Conditions for screening were provided through extensive research by the American College of Medical Genetics (ACMG) under the U.S. Department of Health and Human Services (HHS) supervision. Recently, ACMG has deviated from the traditional screening criteria and added new conditions to the list. The newborn screening program is diligently followed in all the states of North America. In addition, to create awareness, health departments of the states in the U.S. have published free data and created websites that are expected to help parents to cope better with these conditions.
Market Key Players
Key players are AB Sciex, Bio Rad Laboratories, Agilent Technologies, Masimo Corporation, Natus Medical, Trivitron Healthcare, PerkinElmer Inc, GE Life Sciences, ZenTech S.A and Covidien Plc.
Company Profile Analysis:
Covidien Plc: Overview:
Covidien was an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. Covidien became an independent publicly traded company after being spun off from Tyco International in 2007. Covidien's portfolio consists of medical devices, including surgical, respiratory, patient monitoring, gastrointestinal, lung health, and renal care products. The Medical Devices segment includes developing, manufacturing and selling endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. In June 2014, Covidien plc was acquired by Medtronic for $42.9 billion in Cash and Stock. With its expanded portfolio of innovative products and services, this acquisition will allow Medtronic to reach more patients.
Product Portfolio:
Nellcor Pulse Oximetry: The Nellcor pulse oximetry system provides fast, accurate and consistent pulse oximetry performance across a wide range of patients.
Recent Development-
- February 2026: Illumina Inc. expanded its collaboration with international health agencies to promote NGS-based newborn screening programs, focusing on pilot initiatives in Europe and Asia to enable early genomic diagnosis of rare diseases.
- January 2026: Revvity Inc. expanded its newborn screening portfolio by enhancing its tandem mass spectrometry (MS/MS) solutions with improved automation capabilities, enabling faster metabolic disorder detection across U.S. state screening labs and supporting higher throughput requirements.
- December 2025: Thermo Fisher Scientific introduced upgraded genetic analysis workflows for newborn screening, integrating next-generation sequencing (NGS) tools to support early detection of rare inherited disorders, with a focus on improving turnaround time in public health laboratories.
